ATE33839T1 - Neue camptothecin-derivate und verfahren zu deren herstellung. - Google Patents

Neue camptothecin-derivate und verfahren zu deren herstellung.

Info

Publication number
ATE33839T1
ATE33839T1 AT84108257T AT84108257T ATE33839T1 AT E33839 T1 ATE33839 T1 AT E33839T1 AT 84108257 T AT84108257 T AT 84108257T AT 84108257 T AT84108257 T AT 84108257T AT E33839 T1 ATE33839 T1 AT E33839T1
Authority
AT
Austria
Prior art keywords
substituted
ring
group
atom
camptothecin
Prior art date
Application number
AT84108257T
Other languages
English (en)
Inventor
Tadashi Miyasaka
Seigo Sawada
Kenichiro Nokata
Eiichi Sugino
Masahiko Mutai
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Application granted granted Critical
Publication of ATE33839T1 publication Critical patent/ATE33839T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT84108257T 1983-07-14 1984-07-13 Neue camptothecin-derivate und verfahren zu deren herstellung. ATE33839T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58126946A JPS6019790A (ja) 1983-07-14 1983-07-14 新規なカンプトテシン誘導体
EP84108257A EP0137145B1 (de) 1983-07-14 1984-07-13 Neue Camptothecin-Derivate und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
ATE33839T1 true ATE33839T1 (de) 1988-05-15

Family

ID=14947803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84108257T ATE33839T1 (de) 1983-07-14 1984-07-13 Neue camptothecin-derivate und verfahren zu deren herstellung.

Country Status (8)

Country Link
US (1) US4604463A (de)
EP (1) EP0137145B1 (de)
JP (1) JPS6019790A (de)
AT (1) ATE33839T1 (de)
CA (1) CA1235415A (de)
DE (2) DE137145T1 (de)
LU (1) LU90074I2 (de)
NL (1) NL980026I2 (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
US6407115B1 (en) * 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5637770A (en) * 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
NZ245112A (en) 1991-11-15 1995-07-26 Smithkline Beecham Corp Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
US6177439B1 (en) 1995-06-06 2001-01-23 Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
US6214836B1 (en) 1995-06-06 2001-04-10 Dr. Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
WO1996040886A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
DE69728152T2 (de) * 1996-08-19 2004-08-05 Bionumerik Pharmaceuticals, Inc., San Antonio Hoch-lipophile campothecin-derivate
JP2001513105A (ja) * 1997-02-27 2001-08-28 フアルマシア・アンド・アツプジヨン・カンパニー 塩酸イリノテカン誘発性下痢軽減治療薬としてのタモキシフェン
JP3046258B2 (ja) * 1997-04-11 2000-05-29 株式会社ヤクルト本社 １−クロロカルボニル−４−ピペリジノピペリジンまたはその塩酸塩の製造方法
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
DK1102594T3 (da) * 1998-08-05 2002-08-26 Aventis Pharma Sa Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6159935A (en) 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
IL150953A0 (en) 2000-02-28 2003-02-12 Aventis Pharma Sa A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
CA2408710C (en) * 2000-05-15 2010-01-26 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
DE60118571T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
KR100742524B1 (ko) 2000-10-27 2007-08-02 아방티 파르마 소시에테 아노님 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ES2287495T3 (es) * 2002-03-01 2007-12-16 Pfizer Italia S.R.L. Forma polimorfa cristalina de clorhidrato de irinotecan.
WO2003090785A1 (en) * 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Llc Methods and conpositions for treating, preventing or delaying onset of a neoplasm
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
CN100363366C (zh) * 2002-06-27 2008-01-23 中国科学院上海药物研究所 一类喜树碱衍生物及制备方法
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
CN100344633C (zh) 2003-05-12 2007-10-24 台湾神隆股份有限公司 用于制备7－烷基－10－羟基－20(s)－喜树碱的方法
US7067666B2 (en) * 2003-06-27 2006-06-27 Research Triangle Institute 7-substituted camptothecin and camptothecin analogs and methods for producing the same
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
WO2005062985A2 (en) * 2003-12-23 2005-07-14 American Bioscience, Inc. Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
US20080242691A1 (en) * 2004-02-13 2008-10-02 Kabushiki Kaisha Yakult Honsha Aqueous Solution Preparation Containing Camptothecins
AU2005244768B2 (en) 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
US20050267141A1 (en) * 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
ES2594621T3 (es) 2004-06-01 2016-12-21 Kabushiki Kaisha Yakult Honsha Preparación de irinotecán
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
EP3085361A1 (de) 2004-09-07 2016-10-26 Biocompatibles UK Limited Zusammensetzungen mit camptothecinen in mikrosphären
JP4829120B2 (ja) * 2004-10-01 2011-12-07 株式会社ヤクルト本社 イリノテカン酸付加塩
US7205385B2 (en) * 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
WO2006082053A1 (en) * 2005-02-02 2006-08-10 Heidelberg Pharma Gmbh 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives
DE602006009901D1 (de) * 2005-02-07 2009-12-03 Fermion Oy Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin
CA2591071C (en) * 2005-02-08 2014-04-29 Fermion Oy Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
CA2591074C (en) * 2005-02-08 2015-01-20 Fermion Oy Preparation method
EP1853243A2 (de) * 2005-03-04 2007-11-14 Novacea, Inc. Behandlung hyperproliferativer krankheiten mit anthrachinonen
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
US7994186B2 (en) * 2005-04-18 2011-08-09 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
AU2006270297B2 (en) * 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
NZ565654A (en) * 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
WO2007015259A2 (en) * 2005-08-03 2007-02-08 Avra Laboratories Pvt. Ltd. Method of synthesizing key intermediates for the production of camptothecin derivatives
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
US7435818B2 (en) 2005-09-20 2008-10-14 Scinopharm Taiwan, Ltd. Crystal forms of irinotecan hydrochloride
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN1982313B (zh) * 2005-12-13 2010-12-01 深圳市天和医药科技开发有限公司 10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
EP1803725A1 (de) * 2005-12-13 2007-07-04 W.C. Heraeus GmbH Verfahren zur Herstellung von Irinotecan
US20070208050A1 (en) * 2006-02-24 2007-09-06 Palle Venkata Raghavendra Acha Process for preparing irinotecan
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
EP1998809B1 (de) * 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Konjugate von camptothecin und zelldurchdringenden peptiden und deren pharmazeutische zusammensetzungen.
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2699184A1 (en) * 2006-09-22 2008-03-27 Labopharm Inc. Compositions and methods for ph targeted drug delivery
EA200970353A1 (ru) * 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
US20090062323A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched irinotecan
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
JPWO2009054332A1 (ja) 2007-10-23 2011-03-03 萬有製薬株式会社 ピリドン置換ジヒドロピラゾロピリミジノン誘導体
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
EP2269072B1 (de) 2008-03-31 2017-08-23 Boston Medical Center Corporation Vorhersagemarker für topoisomerase-i-inhibitoren
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376515A1 (de) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthese von purinnukleosiden
CA2748057C (en) * 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
JP2012518598A (ja) 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
US8481503B2 (en) 2009-03-06 2013-07-09 Merck Sharp & Dohme Corp. Combination cancer therapy with an AKT inhibitor and other anticancer agents
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2011063156A2 (en) * 2009-11-18 2011-05-26 Nektar Therapeutics Acid salt forms of polymer-drug conjugates and alkoxylation methods
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
JP2013540694A (ja) 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
EP2655401B1 (de) 2010-12-20 2016-03-09 The Regents of the University of Michigan Hemmer der bindeinteraktion des epidermalen wachstumsfaktor-rezeptor-wärmeschock-proteins 90
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013093931A2 (en) 2011-09-19 2013-06-27 Sun Pharma Advanced Research Company Ltd. Novel prodrugs of phenolic drugs
TR201808733T4 (tr) 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014070233A1 (en) 2012-10-29 2014-05-08 Boston Medical Center Corporation Brca1 mutations as predictive markers for topoisomerase i inhibitors
CN103848840A (zh) * 2012-12-03 2014-06-11 中国人民解放军军事医学科学院毒物药物研究所 喜树碱衍生物及其医药用途
CN103864810A (zh) * 2012-12-07 2014-06-18 天津科技大学 一种新颖的10-羟基喜树碱10位衍生物制备方法及其在抗肿瘤药物中的应用
RS60958B1 (sr) 2013-03-27 2020-11-30 Taiho Pharmaceutical Co Ltd Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
EP2881396A1 (de) * 2013-12-03 2015-06-10 Synbias Pharma AG Verfahren zur Synthese von Irinotecan
JP6704345B2 (ja) * 2014-01-17 2020-06-03 オンコラル ファーマ エーピーエス 癌治療のためのイリノテカンの固体経口剤形
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016203337A2 (en) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions and methods for the treatment of cancer
WO2016203352A2 (en) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions and methods for the treatment of cancer
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
IL257149B2 (en) 2015-08-21 2024-11-01 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
EP3535026A1 (de) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Behandlung von magenkrebs durch kombinationstherapien mit liposomalem irinotecan, oxaliplatin, 5-fluoruracil (und leucovorin)
CN108570057A (zh) * 2017-03-13 2018-09-25 烟台药物研究所 一种合成7-乙基-10-羟基喜树碱的方法
MX2020001451A (es) 2017-08-07 2020-08-06 Amgen Inc Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
EP3669890A1 (de) 2018-12-18 2020-06-24 Croda International PLC Filamentöse nanopartikel mit impfstoffadjuvanswirkung
EP3941944A4 (de) 2019-03-20 2022-11-30 The Regents of the University of California Bispezifische claudin-6-antikörper
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
US20220160872A1 (en) 2019-04-09 2022-05-26 The Board Of Trustees Of The University Of Illinois Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery
JP2022530241A (ja) 2019-04-30 2022-06-28 インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤
US12558407B2 (en) 2019-05-02 2026-02-24 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
EP3986441A1 (de) 2019-06-24 2022-04-27 Amgen Inc. Inhibierung von sirp-gamma zur krebsbehandlung
CN111171077A (zh) * 2020-01-19 2020-05-19 上海交通大学医学院附属仁济医院 喜树碱衍生物及其制备方法和应用
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
EP4477674A1 (de) 2022-02-09 2024-12-18 Daiichi Sankyo Company, Limited Auf umwelteinflüsse reagierender maskierter antikörper und verwendung davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
JPS5198300A (en) * 1975-02-20 1976-08-30 Kanputoteshin oyobi sonoruijitaino seizoho
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) * 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154583A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体

Also Published As

Publication number Publication date
EP0137145B1 (de) 1988-04-27
EP0137145A1 (de) 1985-04-17
JPH034077B2 (de) 1991-01-22
JPS6019790A (ja) 1985-01-31
NL980026I2 (nl) 1999-02-01
LU90074I2 (fr) 1997-08-21
CA1235415A (en) 1988-04-19
DE137145T1 (de) 1985-11-21
DE3470744D1 (en) 1988-06-01
US4604463A (en) 1986-08-05
NL980026I1 (nl) 1998-11-02

Similar Documents

Publication Publication Date Title
ATE33839T1 (de) Neue camptothecin-derivate und verfahren zu deren herstellung.
KR950014097A (ko) 피페라진 유도체
GB1303081A (de)
IE810392L (en) Hydropyridine derivatives.
ATE36859T1 (de) 4'-demethyl-4-epipodophyllotoxin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
GB1489280A (en) Indazole derivatives
KR840005145A (ko) 카르바페넴 항생제의 제조방법
ES8604985A1 (es) Un procedimiento para producir un complejo de platino-diamino
KR850005829A (ko) 2-시아노벤즈이미다졸 유도체의 제조방법
EP0206802A3 (en) Substituted quinoline derivatives
AU547792B2 (en) Pyrimido(5,4-d)pyrimidines
HUP0100453A1 (hu) Eljárás izokarbamidok előállítására
ATE27817T1 (de) Phenylpiperazin-derivate und verfahren zu deren herstellung.
ES8103007A1 (es) Un procedimiento para la preparacion de derivados de 2-hidroxinaftaleno.
GB1470178A (en) Gelating hardening process
AU5608090A (en) Amines
ATE42295T1 (de) Penem-derivate, verfahren zu deren herstellung, ihre verwendung und pharmazeutische zusammensetzungen.
ES8801298A3 (es) Un procedimiento para la preparacion de un complejo de platino
ATE61577T1 (de) Fluorierte abkoemmlinge von vitamin-d3 und verfahren zu deren herstellung.
GB1363415A (en) Bis-pyridyl amine compounds
GB1507414A (en) Hydantoin derivatives
DE69201848D1 (de) Verfahren zum Härten von Gelatine.
ES451209A1 (es) Procedimiento de fabricacion de sulfoximidas sustituidas y sus sales medicamentosas.
KR840007871A (ko) 폴리 사이클릭 비스 아미딘 유도체의 제조방법
GB1374339A (en) Aminoquinoline derivatives and their production